Updates are available Correction dated 2023-04-12
Click to view Correction: https://doi.org/10.1038/s41523-023-00532-3
-
Authors
Dieci, Maria Vittoria https://orcid.org/0000-0002-3967-9861
Bisagni, Giancarlo
Bartolini, Stefania
Frassoldati, Antonio https://orcid.org/0000-0003-3487-3259
Vicini, Roberto https://orcid.org/0000-0002-1799-6567
Balduzzi, Sara https://orcid.org/0000-0003-1205-1895
D’amico, Roberto
Conte, Pierfranco
Guarneri, Valentina https://orcid.org/0000-0002-2375-8397
- License Information
-
More Information
Article History
Received: 26 September 2022
Accepted: 21 January 2023
First Online: 4 February 2023
Change Date: 12 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41523-023-00532-3
Competing interests
: M.V.D. reports personal fees from Eli Lilly, Exact Sciences, Novartis, Pfizer, Seagen, Gilead, MSD, AstraZeneca, and Daiichi Sankyo outside the submitted work. A.F. reports personal fees from Roche, Novartis, Eli Lilly, AstraZeneca, Daiichi Sankyo, Seagen, and Gilead, outside the submitted work. P.C. reports personal fees from Novartis, Eli Lilly, AstraZeneca, Tesaro, Daiichi Sankyo, and Gilead, revealing Genomics, BMS, and Roche outside the submitted work. V.G. reports personal fees from Eli Lilly, Exact Sciences, Novartis, Pfizer, Gilead, MSD, Amgen, Sanofi, Merck Serono, and Eisai outside the submitted work. The remaining authors declare no competing interests.
: The trial was approved by local ethical Committees of all participating centers and conducted in compliance with the principles of Good Clinical Practice and the Declaration of Helsinki.
: All patients signed an informed consent form.
